Alterity gains FDA feedback on ATH434 Phase 3 plan
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.
Positive
- Regulatory alignment with the FDA on clinical pharmacology and non-clinical elements of the ATH434 Phase 3 program in Multiple System Atrophy, marking tangible progress toward a pivotal trial.
- ATH434 has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA, with additional positive data in an open-label Phase 2 study in advanced disease.
- An End-of-Phase 2 meeting for ATH434 remains on track for mid-year 2026, providing a clear near-term regulatory milestone for confirming the Phase 3 path.
Negative
- None.
Insights
Positive FDA feedback advances ATH434 toward Phase 3 in MSA.
Alterity Therapeutics obtained written FDA feedback after a Type C Meeting on its ATH434 program in Multiple System Atrophy. The agency supported the company’s plans for clinical pharmacology and non-clinical development, indicating regulatory alignment in two important technical domains.
This progress is an early but meaningful milestone on the path to a pivotal Phase 3 trial. Remaining steps include securing agreement on Chemistry, Manufacturing, and Controls (CMC) and finalizing Phase 3 trial design. The company expects an End-of-Phase 2 meeting by mid-year 2026, which will be key to confirming the registrational pathway.
ATH434 has already demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 MSA trial, plus positive data in an open-label Phase 2 in advanced MSA. The regulatory and clinical data together suggest steady advancement of the program, though ultimate approval will depend on Phase 3 outcomes and ongoing FDA interactions.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Alterity Therapeutics (ATHE) announce regarding the FDA and ATH434?
What is ATH434 and which disease is Alterity Therapeutics targeting?
What progress has ATH434 shown in clinical trials so far?
What are the next regulatory steps for Alterity Therapeutics and ATH434?
How does the FDA Type C Meeting affect Alterity Therapeutics’ Phase 3 plans?
What therapeutic focus does Alterity Therapeutics (ATHE) have beyond ATH434?
AI-generated analysis. How Rhea-AI works. Not financial advice.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
|
99.1 |
ATH - Alterity Receives Positive FDA Feedback From Type C Meeting |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Alterity Therapeutics Limited |
||
|
By: |
/s/ Julian Babarczy |
|
|
Julian Babarczy |
||
|
Chairman |
||
Date: March 30, 2026
Exhibit 99.1
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
– Alignment reached on key elements of ATH434 Phase 3 development program –
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 March 2026: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA).
The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans related to the clinical pharmacology and non-clinical development elements of the program.
“This meeting confirms alignment with the FDA in two key disciplines and represents an important step toward initiation of the Phase 3 program,” said David Stamler, M.D., Chief Executive Officer of Alterity. “In addition, we will also be seeking agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design. Today’s favorable outcome sets the stage for our future discussions, culminating in an End-of-Phase 2 meeting that remains on track for mid-year 2026.”
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by the Board of Alterity Therapeutics Limited.
Contacts:
Investors:
Tara Speranza
Head of Investor Relations and Communications
tsperanza@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.